Small Cell Lung Cancers: A New Immunotherapy Allows for a 'Never Seen Before' Survival Gain

At the ESMO congress in Madrid, Jacob Sands presented groundbreaking results from a clinical trial on a dual immunotherapy for extensive small cell lung cancer. This treatment, given after chemotherapy, showed a 58% reduction in mortality risk. Small cell lung cancer is aggressive, accounting for about 15% of lung cancers in France, with rapid progression in advanced stages. The findings were met with enthusiasm from the audience of 8,000 medical professionals.